A multinational research team led by Columbia University and the La Jolla Institute for Immunology has identified a novel viral target that could help combat the global resurgence of measles.
New images of one of the brain’s fastest-acting proteins—the kainate receptor—are providing critical clues that may lead to targeted therapies for epilepsy and other brain disorders.
In children with certain autism mutations, the diversity and severity of symptoms are often related to the identity and properties of gene units, called exons, targeted by the mutations.
A study of more than 1 million patients has found no increased risk of COVID-19 diagnosis, hospitalization, or complications for users of two common anti-hypertensive medications.
Columbia researchers created a new technology using synthetic llama antibodies to protect endangered proteins inside cells. The technology could treat dozens of diseases.
Researchers at Columbia, UCLA, and Northeastern have begun helping the FDA in its effort to monitor the safety and effectiveness of vaccines, including COVID-19 vaccines, and other biologic products.
Columbia researchers characterized a new class of ‘biomimetic’ drugs that plug a calcium channel implicated in the development of cancer and several other diseases.
A new nationwide study of more than 50,000 individuals—coordinated by Columbia researchers—is now underway to determine factors that predict disease severity and long-term health impacts of COVID-19.
Ancient parts of the brain may hold secrets that help explain the drive to eat and how eating may affect brain health. Sabrina Diano, the new Institute of Human Nutrition director, is investigating.
Immunotherapy, often ineffective against stomach cancer, was more effective when combined with chemotherapy and given earlier, finds a new study in mice.